New  	New  	 JJ	B-NP
advances  	advances  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
pathogenesis  	pathogenesis  	 NN	B-NP
of  	of  	 IN	I-NP
ANCA-associated  	ANCA-associated  	 JJ	I-NP
vasculitides  	vasculitides  	 JJ	I-NP
Anti-neutrophil  	Anti-neutrophil  	 JJ	I-NP
cytoplasmic  	cytoplasmic  	 JJ	I-NP
antibody  	antibody  	 NN	I-NP
( 	( 	 -LRB-	I-NP
ANCA 	ANCA 	 NNP	I-NP
) 	) 	 -RRB-	I-NP
-associated  	-associated  	 JJ	I-NP
vasculitides  	vasculitides  	 NNS	I-NP
( 	( 	 -LRB-	O
AAV 	AAV 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
a  	a  	 DT	O
group  	group  	 NN	O
of  	of  	 IN	O
autoimmune  	autoimmune  	 JJ	B-NP
disorders  	disorders  	 NNS	I-NP
including  	including  	 VBG	I-NP
Wegener 	Wegener 	 NNP	I-NP
's  	's  	 POS	O
granulomatosis  	granulomatosis  	 NN	B-NP
( 	( 	 -LRB-	O
WG 	WG 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
microscopic  	microscopic  	 JJ	B-NP
polyangiitis  	polyangiitis  	 NNS	I-NP
( 	( 	 -LRB-	O
MPA 	MPA 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Churg-Strauss  	Churg-Strauss  	 JJ	B-NP
syndrome  	syndrome  	 NN	I-NP
( 	( 	 -LRB-	O
CSS 	CSS 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
renal-limited  	renal-limited  	 JJ	B-NP
vasculitis  	vasculitis  	 NNS	I-NP
( 	( 	 -LRB-	O
RLV 	RLV 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
paper  	paper  	 NN	O
reviews  	reviews  	 VBZ	O
updated  	updated  	 VBN	B-NP
information  	information  	 NN	I-NP
on  	on  	 IN	O
the  	the  	 DT	O
pathogenesis  	pathogenesis  	 NN	B-NP
of  	of  	 IN	I-NP
AAV 	AAV 	 NNP	I-NP
.  	.  	 .	O
Additional  	Additional  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
evidence  	evidence  	 NN	I-NP
for  	for  	 IN	I-NP
a  	a  	 DT	I-NP
pathogenic  	pathogenic  	 JJ	I-NP
role  	role  	 NN	I-NP
of  	of  	 IN	I-NP
ANCA  	ANCA  	 NNP	I-NP
comes  	comes  	 VBZ	O
from  	from  	 IN	O
the  	the  	 DT	O
observation  	observation  	 NN	O
that  	that  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
severe  	severe  	 JJ	O
acute  	acute  	 JJ	O
renal  	renal  	 JJ	B-NP
failure  	failure  	 NN	I-NP
treated  	treated  	 VBN	O
with  	with  	 IN	O
plasma  	plasma  	 JJ	B-NP
exchange  	exchange  	 NN	I-NP
had  	had  	 VBD	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
risk  	risk  	 NN	O
for  	for  	 IN	O
progression  	progression  	 VBG	O
to  	to  	 TO	O
end-stage  	end-stage  	 JJ	B-NP
renal  	renal  	 JJ	I-NP
disease  	disease  	 NN	I-NP
than  	than  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
received  	received  	 VBD	O
intravenous  	intravenous  	 JJ	B-NP
methylprednisolone  	methylprednisolone  	 JJ	I-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
both  	both  	 DT	O
in  	in  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
standard  	standard  	 JJ	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
Recent  	Recent  	 JJ	O
data  	data  	 NNS	O
also  	also  	 RB	O
suggest  	suggest  	 VB	O
that  	that  	 IN	O
antibodies  	antibodies  	 NNS	B-NP
to  	to  	 TO	O
complementary  	complementary  	 VB	B-NP
proteinase-3  	proteinase-3  	 NNP	I-NP
( 	( 	 -LRB-	O
cPR3 	cPR3 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
probably  	probably  	 RB	O
cross-reacting  	cross-reacting  	 JJ	O
with  	with  	 IN	O
plasminogen 	plasminogen 	 NN	B-NP
,  	,  	 ,	O
may  	may  	 MD	O
induce  	induce  	 VB	O
PR3-ANCA 	PR3-ANCA 	 CD	B-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
new  	new  	 JJ	O
ANCA 	ANCA 	 NNP	B-NP
,  	,  	 ,	O
directed  	directed  	 VBN	O
against  	against  	 IN	O
human  	human  	 JJ	O
lysosome  	lysosome  	 FW	B-NP
membrane  	membrane  	 FW	I-NP
protein-2  	protein-2  	 FW	I-NP
( 	( 	 -LRB-	O
LAMP-2 	LAMP-2 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
concurrent  	concurrent  	 JJ	O
with  	with  	 IN	O
PR3-ANCA  	PR3-ANCA  	 NNP	B-NP
or  	or  	 CC	O
MPO-ANCA 	MPO-ANCA 	 JJ	B-NP
,  	,  	 ,	O
was  	was  	 VBD	O
described  	described  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
sensitive  	sensitive  	 JJ	O
and  	and  	 CC	O
specific  	specific  	 JJ	O
marker  	marker  	 NN	O
for  	for  	 IN	O
renal  	renal  	 JJ	B-NP
AAV 	AAV 	 NNP	I-NP
.  	.  	 .	O
In  	In  	 IN	O
vitro 	vitro 	 NN	B-NP
,  	,  	 ,	O
ANCA  	ANCA  	 NNP	B-NP
can  	can  	 MD	O
further  	further  	 RB	O
activate  	activate  	 VBP	O
primed  	primed  	 VBN	O
neutrophils  	neutrophils  	 VBN	O
to  	to  	 TO	O
release  	release  	 VB	O
reactive  	reactive  	 JJ	B-NP
oxygen  	oxygen  	 NN	I-NP
species  	species  	 NNS	I-NP
and  	and  	 CC	O
lytic  	lytic  	 JJ	B-NP
enzymes 	enzymes 	 NN	I-NP
,  	,  	 ,	O
and 	and 	 CC	O
,  	,  	 ,	O
in  	in  	 IN	O
conjunction  	conjunction  	 NN	O
with  	with  	 IN	O
neutrophils 	neutrophils 	 NN	B-NP
,  	,  	 ,	O
damage  	damage  	 NN	O
and  	and  	 CC	O
lyse  	lyse  	 JJ	B-NP
endothelial  	endothelial  	 JJ	I-NP
cells 	cells 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
vivo 	vivo 	 NN	B-NP
,  	,  	 ,	O
transfer  	transfer  	 NN	O
of  	of  	 IN	O
splenocytes  	splenocytes  	 NN	B-NP
from  	from  	 IN	O
myeloperoxidase-deficient  	myeloperoxidase-deficient  	 JJ	B-NP
mice  	mice  	 NNS	I-NP
immunized  	immunized  	 VBN	O
with  	with  	 IN	O
mouse  	mouse  	 NN	B-NP
myeloperoxidase  	myeloperoxidase  	 NN	I-NP
into  	into  	 IN	O
wild-type  	wild-type  	 JJ	B-NP
mice  	mice  	 NNS	I-NP
resulted  	resulted  	 VBD	O
in  	in  	 IN	O
pauci-immune  	pauci-immune  	 JJ	B-NP
systemic  	systemic  	 JJ	I-NP
vasculitis 	vasculitis 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
similar  	similar  	 JJ	O
experiment  	experiment  	 NN	O
in  	in  	 IN	O
PR3-deficient  	PR3-deficient  	 CD	B-NP
mice  	mice  	 NNS	I-NP
did  	did  	 VBD	O
not  	not  	 RB	O
cause  	cause  	 VB	O
significant  	significant  	 JJ	O
vasculitic  	vasculitic  	 JJ	B-NP
lesions 	lesions 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
anti-MPO  	anti-MPO  	 JJ	B-NP
induced  	induced  	 JJ	O
vasculitis  	vasculitis  	 JJ	B-NP
mouse  	mouse  	 NN	I-NP
model 	model 	 NN	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
critical  	critical  	 JJ	B-NP
role  	role  	 NN	I-NP
of  	of  	 IN	I-NP
complement  	complement  	 JJ	I-NP
activation  	activation  	 NN	I-NP
was  	was  	 VBD	O
suggested 	suggested 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
anti-  	anti-  	 JJ	B-NP
LAMP-2  	LAMP-2  	 CD	I-NP
antibody  	antibody  	 NN	I-NP
can  	can  	 MD	O
also  	also  	 RB	O
induce  	induce  	 VB	O
pauci-immune  	pauci-immune  	 JJ	B-NP
necrotizing  	necrotizing  	 JJ	I-NP
crescentic  	crescentic  	 JJ	I-NP
glomerulonephritis  	glomerulonephritis  	 NN	I-NP
in  	in  	 IN	O
rats 	rats 	 NNS	O
.  	.  	 .	O
Rats  	Rats  	 NNS	O
developed  	developed  	 VBD	O
both  	both  	 DT	O
cross-reactive  	cross-reactive  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
to  	to  	 TO	O
LAMP-2  	LAMP-2  	 CD	B-NP
and  	and  	 CC	O
crescentic  	crescentic  	 JJ	B-NP
glomerulonephritis  	glomerulonephritis  	 NN	I-NP
when  	when  	 WRB	O
immunized  	immunized  	 NNS	O
with  	with  	 IN	O
FimH 	FimH 	 NNP	B-NP
,  	,  	 ,	O
an  	an  	 DT	O
adhesin  	adhesin  	 NN	B-NP
from  	from  	 IN	O
Gram-negative  	Gram-negative  	 JJ	B-NP
bacteria  	bacteria  	 NNS	I-NP
which  	which  	 WDT	O
has  	has  	 VBZ	O
strong  	strong  	 JJ	O
homology  	homology  	 NN	B-NP
with  	with  	 IN	O
human  	human  	 JJ	O
LAMP-2 	LAMP-2 	 NN	B-NP
.  	.  	 .	O
Together 	Together 	 RB	O
,  	,  	 ,	O
clinical 	clinical 	 JJ	O
,  	,  	 ,	O
in  	in  	 IN	O
vitro  	vitro  	 NN	B-NP
and  	and  	 CC	O
in  	in  	 IN	O
vivo  	vivo  	 JJ	B-NP
data  	data  	 NNS	I-NP
support  	support  	 VBP	O
a  	a  	 DT	O
pathogenic  	pathogenic  	 JJ	B-NP
role  	role  	 NN	I-NP
for  	for  	 IN	I-NP
ANCA  	ANCA  	 NNP	I-NP
in  	in  	 IN	O
AAV 	AAV 	 NNP	B-NP
,  	,  	 ,	O
although  	although  	 IN	O
this  	this  	 DT	O
role  	role  	 NN	O
is  	is  	 VBZ	O
more  	more  	 RBR	O
evident  	evident  	 JJ	O
for  	for  	 IN	O
myeloperoxidase-ANCA  	myeloperoxidase-ANCA  	 JJ	B-NP
than  	than  	 IN	O
for  	for  	 IN	O
PR3-ANCA 	PR3-ANCA 	 CD	B-NP
.  	.  	 .	O
The  	The  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
anti-  	anti-  	 NNP	B-NP
LAMP-2  	LAMP-2  	 NNP	I-NP
requires  	requires  	 VBZ	O
further  	further  	 JJ	O
studies 	studies 	 NNS	O
.  	.  	 .	O
